Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology-Reference-Cited by-同舟云学术

Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology

Published:2022-04 Issue:4 Volume:20 Page:387-405
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Thompson John A.¹,Schneider Bryan J.²,Brahmer Julie³,Achufusi Amaka⁴,Armand Philippe⁵,Berkenstock Meghan K.³,Bhatia Shailender¹,Budde Lihua E.⁶,Chokshi Saurin⁷,Davies Marianne⁸,Elshoury Amro⁹,Gesthalter Yaron¹⁰,Hegde Aparna¹¹,Jain Michael¹²,Kaffenberger Benjamin H.¹³,Lechner Melissa G.¹⁴,Li Tianhong¹⁵,Marr Alissa¹⁶,McGettigan Suzanne¹⁷,McPherson Jordan¹⁸,Medina Theresa¹⁹,Mohindra Nisha A.²⁰,Olszanski Anthony J.²¹,Oluwole Olalekan²²,Patel Sandip P.²³,Patil Pradnya²⁴,Reddy Sunil²⁵,Ryder Mabel²⁶,Santomasso Bianca²⁷,Shofer Scott²⁸,Sosman Jeffrey A.²⁰,Wang Yinghong²⁹,Zaha Vlad G.³⁰,Lyons Megan³¹,Dwyer Mary³¹,Hang Lisa³¹

Affiliation:

1. 1Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

2. 2University of Michigan Rogel Cancer Center;

3. 3The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

4. 4University of Wisconsin Carbone Cancer Center;

5. 5Dana-Farber/Brigham and Women’s Cancer Center;

6. 6City of Hope National Medical Center;

7. 7St. Jude Children's Research Hospital/The University of Tennessee Health Science Center;

8. 8Yale Cancer Center/Smilow Cancer Hospital;

9. 9Roswell Park Comprehensive Cancer Center;

10. 10UCSF Helen Diller Family Comprehensive Cancer Center;

11. 11O'Neal Comprehensive Cancer Center at UAB;

12. 12Moffitt Cancer Center;

13. 13The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

14. 14UCLA Jonsson Comprehensive Cancer Center;

15. 15UC Davis Comprehensive Cancer Center;

16. 16Fred & Pamela Buffett Cancer Center;

17. 17Abramson Cancer Center at the University of Pennsylvania;

18. 18Huntsman Cancer Institute at the University of Utah;

19. 19University of Colorado Cancer Center;

20. 20Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

21. 21Fox Chase Cancer Center;

22. 22Vanderbilt-Ingram Cancer Center;

23. 23UC San Diego Moores Cancer Center;

24. 24Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

25. 25Stanford Cancer Institute;

26. 26Mayo Clinic Cancer Center;

27. 27Memorial Sloan Kettering Cancer Center;

28. 28Duke Cancer Institute;

29. 29The University of Texas MD Anderson Cancer Center;

30. 30UT Southwestern Simmons Comprehensive Cancer Center; and

31. 31National Comprehensive Cancer Network

Abstract

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions, consisting of medical and hematologic oncologists with expertise across a wide range of disease sites, and experts from the areas of dermatology, gastroenterology, endocrinology, neurooncology, nephrology, cardio-oncology, ophthalmology, pulmonary medicine, and oncology nursing. The content featured in this issue is an excerpt of the recommendations for managing toxicities related to CAR T-cell therapies and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to immune checkpoint inhibitors, visitNCCN.org.

Publisher

Harborside Press, LLC

Subject

Oncology

Link

https://jnccn.org/downloadpdf/journals/jnccn/20/4/article-p387.xml

Reference234 articles.

1. Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells;Park;Clin Infect Dis,2018

2. Chimeric antigen receptor T-cell therapy for the community oncologist;Maus;Oncologist,2016

3. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma;Lee;Br J Haematol,2016

4. Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy;Gardner;Blood,2019

5. BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population;Thompson;J Exp Med,2000

Cited by 120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitors break whose heart? Perspectives from cardio-immuno-oncology;Genes & Diseases;2024-03

2. A case report of lung metastasis in a cervical cancer presenting as a consolidation;Radiology Case Reports;2024-03

3. Immunotherapy-induced adverse events in metastatic renal cell carcinoma: A case of rapid response and complex challenges;Urology Case Reports;2024-02

4. Optimizing the CAR T-Cell Therapy Experience in Multiple Myeloma: Clinical Pearls From an Expert Roundtable;Clinical Lymphoma Myeloma and Leukemia;2024-02

5. Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology;Frontiers in Cardiovascular Medicine;2024-01-23